Clinical trial
Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic…
NCT00089154 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00089154 |
|---|---|
| Title | Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
| Official title | A Phase II Study of Thrice Weekly Apolizumab in Patients With Chronic Lymphocytic Leukemia : CRC Master Protocol |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Small Lymphocytic Lymphoma |
| Intervention type | Biological, Other |
| Interventions | apolizumab, laboratory biomarker analysis, pharmacological study |
| Enrollment | 32 |
| Start date | Aug 1, 2004 |
| Primary completion | Oct 1, 2005 |
| First posted | Aug 5, 2004 |
| Last update posted | Jul 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: